Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 17/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452981 | 0.92 | OXTR (0.46) | OXTRAVPR1AMEN1KMT2AAVPR2 | |
| SCHEMBL2448152 | 0.90 | PIK3CA (0.35) | OXTRAVPR1A | |
| SCHEMBL2451262 | 0.90 | PIK3CA (0.35) | OXTRAVPR1A | |
| SCHEMBL1225623 | 0.86 | STIM1 (0.41) | — | |
| SCHEMBL1110867 | 0.86 | PIK3CA (0.40) | OXTRMEN1KMT2A | |
| SCHEMBL1225381 | 0.84 | PIK3CA (0.42) | — | |
| SCHEMBL1076571 | 0.84 | SMN1; SMN2 (0.38) | MEN1KMT2A | |
| SCHEMBL1073735 | 0.84 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL1073182 | 0.84 | OXTR (0.41) | OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL1074241 | 0.83 | SMN1; SMN2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-22 | — | — | US | claimed |
| EP-2201001-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-14 | — | — | EP | claimed |
| EP-2201001-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | claimed |
| WO-2009053101-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | claimed |
| EP-2053046-A1 | Novel imidazole derivatives | Syngeta Participations AG (CH) | 2009-04-29 | — | — | EP | claimed |
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2201001-B1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| EP-2201001-A1 | NOVEL IMIDAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009053101-A1 | NOVEL IMIDAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| EP-2053046-A1 | Novel imidazole derivatives | Syngeta Participations AG (CH) | 2009-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311649-A1 | NOVEL IMIDAZOLE DERIVATIVES | CBR3, C3AR1, C1R | OXTR 1079/4885AVPR1A 2711/4885MEN1 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.